Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with Colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516.
   PubMed Web of Science ®Google Scholar
• Osterman E, Ekstrom J, Sjoblom T, et al. Accurate population-based model for individual prediction of Colon cancer recurrence. Acta Oncol. 2021;60(10):1241–1249.
   PubMed Web of Science ®Google Scholar
• Osterman E, Hammarstrom K, Imam I, et al. Recurrence risk After radical colorectal cancer surgery–less Than Before, But how high Is It? Cancers. 2020;12(11):3308.
   Web of Science ®Google Scholar
• Glimelius B, Cavalli Björkman N. Metastatic colorectal cancer: Current treatment and future options for improved survival. Medical approach–present status. Scand J Gastroenterol. 2012;47(3):296–314.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of First-Line chemotherapy combined With cetuximab or bevacizumab on overall survival in patients With KRAS Wild-Type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–2401.
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer. 2021;124(3):587–594.
   PubMed Web of Science ®Google Scholar
• Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019;3(1):50–56.
   PubMed Web of Science ®Google Scholar
• Atreya CE, Yaeger R, Chu E. Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches. Am Soc Clin Oncol Educ Book. 2017;37:246–256.
   PubMedGoogle Scholar
• Lambert PC, Dickman PW, Osterlund P, et al. Temporal trends in the proportion cured for cancer of the Colon and rectum: a population-based study using data from the finnish cancer registry. Int J Cancer. 2007;121(9):2052–2059.
   PubMed Web of Science ®Google Scholar
• Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, et al. Significant improvement in survival of patients presenting with metastatic Colon cancer in the South of The Netherlands from 1990 to 2004. Ann Oncol. 2008;19(9):1600–1604.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–3683.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer. 2009;115(20):4679–4687.
   PubMed Web of Science ®Google Scholar
• Lemmens VE, de Haan N, Rutten HJ, et al. Improvements in population-based survival of patients presenting with metastatic rectal cancer in the South of The Netherlands, 1992-2008. Clin Exp Metastasis. 2011;28(3):283–290.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Cvancarova M, Qvortrup C, et al. Age-dependent improvement in median and long-term survival in unselected population-based nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol. 2013;24(9):2354–2360.
   PubMed Web of Science ®Google Scholar
• Mitry E, Rollot F, Jooste V, et al. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer. 2013;49(13):2919–2925.
   PubMed Web of Science ®Google Scholar
• Castleberry AW, Guller U, Tarantino I, et al. Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. J Gastrointest Surg. 2014;18(6):1194–1204.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Hennequin A, Drouillard A, et al. Epidemiology and prognosis of synchronous and metachronous Colon cancer metastases: a french population-based study. Dig Liver Dis. 2014;46(9):854–858.
   PubMedGoogle Scholar
• van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32(5):457–465.
   PubMed Web of Science ®Google Scholar
• Hamers PAH, Elferink MAG, Stellato RK, et al. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. Int J Cancer. 2021;148(2):296–306.
   PubMed Web of Science ®Google Scholar
• Krell RW, Regenbogen SE, Wong SL. Variation in hospital treatment patterns for metastatic colorectal cancer. Cancer. 2015;121(11):1755–1761.
   PubMed Web of Science ®Google Scholar
• Keikes L, Koopman M, Stuiver MM, et al. Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. Acta Oncol. 2020;59(4):395–403.
   PubMed Web of Science ®Google Scholar
• Lao C, Kuper-Hommel M, Laking G, et al. Evidence of inequitable use of chemotherapy in New Zealand colorectal cancer patients. N Z Med J. 2020;133(1520):15–26.
   PubMed Web of Science ®Google Scholar
• White A, Ironmonger L, Steele RJC, et al. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. BMC Cancer. 2018;18(1):906.
   PubMedGoogle Scholar
• Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated With age disparities Among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–1773.
   PubMed Web of Science ®Google Scholar
• Kodeda K, Nathanaelsson L, Jung B, et al. Population-based data from the swedish Colon cancer registry. Br J Surg. 2013;100(8):1100–1107.
   PubMed Web of Science ®Google Scholar
• RCC. Nationella kvalitetsregister cancer. https://wwwcancercentrumse/sydost/vara-uppdrag/kunskapsstyrning/kvalitetsregister/. 2020.
   Google Scholar
• Moberger P, Skoldberg F, Birgisson H. Evaluation of the swedish colorectal cancer registry: an overview of completeness, timeliness, comparability and validity. Acta Oncol. 2018;57(12):1611–1621.
   PubMed Web of Science ®Google Scholar
• Osterman E, Hammarstrom K, Imam I, et al. Completeness and accuracy of the registration of recurrences in the swedish colorectal cancer registry (SCRCR) and an update of recurrence risk in Colon cancer. Acta Oncol. 2021;Mar 9:1–8. Online ahead of print. PMID: 33689551.
   Google Scholar
• RCC. Regionala rapporter. https://wwwcancercentrumse/norr/cancerdiagnoser/tjocktarm-andtarm-och-anal/tjock–och-andtarm/kvalitetsregister/. 2020;Accessed Dec 8, 2020.
   Google Scholar
• Van Cutsem E, Nordlinger B, Cervantes A, ESMO Guidelines Working Group, et al. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21 Suppl 5:v93–7.
   PubMedGoogle Scholar
• Goey KK, t Lam-Boer J, de Wilt JH, et al. Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. Eur J Cancer. 2016;69:166–177.
   PubMed Web of Science ®Google Scholar
• Stensrud MJ, Hernán MA. Why test for proportional hazards? Jama. 2020;323(14):1401–1402.
   PubMed Web of Science ®Google Scholar
• Riihimaki M, Hemminki A, Sundquist J, et al. Patterns of metastasis in Colon and rectal cancer. Sci Rep. 2016;6:29765.
   PubMed Web of Science ®Google Scholar
• Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014;106(3):dju002.
   PubMedGoogle Scholar
• Heinemann V, Stintzing S. FOLFIRI with cetuximab or bevacizumab: FIRE-3-Authors’ reply. Lancet Oncol. 2014;15(13):e583-4–e584.
   Web of Science ®Google Scholar
• Platell C, Ng S, O'Bichere A, et al. Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum. 2011;54(2):214–219.
   PubMed Web of Science ®Google Scholar
• Golan T, Urban D, Berger R, et al. Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location. Cancer. 2013;119(16):3084–3091.
   PubMed Web of Science ®Google Scholar
• Siebenhuner AR, Guller U, Warschkow R. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. BMC Cancer. 2020;20(1):246.
   PubMed Web of Science ®Google Scholar
• Shen C, Tannenbaum D, Horn R, et al. Overall survival in phase 3 clinical trials and the surveillance, epidemiology, and end results database in patients With metastatic colorectal cancer, 1986-2016: a systematic review. JAMA Netw Open. 2022;5(5):e2213588.
   PubMed Web of Science ®Google Scholar
• Sahin IH, Klostergaard J. BRAF mutations as actionable targets: a paradigm shift in the management of colorectal cancer and novel avenues. J Clin Oncol Oncol Pract. 2021;17(12):723–730.
   Google Scholar
• Damilakis E, Mavroudis D, Sfakianaki M, et al. Immunotherapy in metastatic colorectal cancer: Could the latest developments hold the key to improving patient survival? Cancers (Basel). 2020;12(4):889.
   Web of Science ®Google Scholar
• Nunes L, Aasebo K, Mathot L, et al. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncol. 2020;59(4):417–426.
   PubMed Web of Science ®Google Scholar
• Kumar R, Price TJ, Beeke C, et al. Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clin Colorectal Cancer. 2014;13(2):87–93.
   PubMed Web of Science ®Google Scholar
• Hammerman A, Greenberg-Dotan S, Battat E, et al. The 'real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large israeli retrospective cohort study. Acta Oncol. 2015;54(2):164–170.
   PubMed Web of Science ®Google Scholar
• Stein A, Petersen V, Schulze M, et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large german community-based observational cohort study. Acta Oncol. 2015;54(2):171–178.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Karapetis CS, Ullah S, et al. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncol. 2016;55(4):480–485.
   PubMed Web of Science ®Google Scholar
• Young AL, Adair R, Culverwell A, et al. Variation in referral practice for patients with colorectal cancer liver metastases. Br J Surg. 2013;100(12):1627–1632.
   PubMed Web of Science ®Google Scholar
• Hackl C, Neumann P, Gerken M, et al. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.
   PubMed Web of Science ®Google Scholar
• Noren A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. Eur J Cancer. 2016;53:105–114.
   PubMed Web of Science ®Google Scholar
• Angelsen JH, Horn A, Sorbye H, et al. Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. Br J Surg. 2017;104(5):580–589.
   PubMed Web of Science ®Google Scholar
• Noren A, Sandstrom P, Gunnarsdottir K, et al. Identification of inequalities in the selection of liver surgery for colorectal liver metastases in Sweden. Scand J Surg. 2018;107(4):294–301.
   PubMed Web of Science ®Google Scholar
• Engstrand J, Nilsson H, Stromberg C, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78.
   PubMed Web of Science ®Google Scholar
• Adam L, San Lucas FA, Fowler R, et al. DNA sequencing of small bowel adenocarcinomas identifies targetable recurrent mutations in the ERBB2 signaling pathway. Clin Cancer Res. 2019;25(2):641–651.
   PubMed Web of Science ®Google Scholar
• Nitsche U, Stöß C, Stecher L, et al. Meta-analysis of outcomes following resection of the primary tumour in patients presenting with metastatic colorectal cancer. Br J Surg. 2018;105(7):784–796.
   PubMed Web of Science ®Google Scholar
• Arbman G, Pahlman L, Glimelius B. The rise and fall of a longed for clinical trial in patients with generalized colorectal cancer. Acta Oncol. 2013;52(8):1779–1782.
   PubMed Web of Science ®Google Scholar
• van der Kruijssen DEW, Elias SG, Vink GR, CAIRO4 Working Group, et al. Sixty-Day mortality of patients With metastatic colorectal cancer randomized to systemic treatment vs primary tumor resection followed by systemic treatment: the CAIRO4 phase 3 randomized clinical trial. JAMA Surg. 2021;156(12):1093–1101.
   PubMed Web of Science ®Google Scholar